Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

36.4%

8 terminated/withdrawn out of 22 trials

Success Rate

63.6%

-22.9% vs industry average

Late-Stage Pipeline

45%

10 trials in Phase 3/4

Results Transparency

86%

12 of 14 completed trials have results

Key Signals

12 with results6 terminated

Enrollment Performance

Analytics

Phase 3

10(45.5%)

Phase 2

6(27.3%)

Phase 1

5(22.7%)

N/A

1(4.5%)

22Total

Phase 3(10)

Phase 2(6)

Phase 1(5)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (22)

Showing 20 of 22 trials

NCT03614156Phase 3Terminated

Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD)

Role: lead

NCT03560518Phase 3Terminated

Study of Rapastinel as Monotherapy in Patients With MDD

Role: lead

NCT03352453Phase 2Terminated

A Study of Rapastinel for Rapid Treatment of Depression and Suicidality in Major Depressive Disorder

Role: lead

NCT03675776Phase 3Terminated

Study of Rapastinel as Monotherapy in Patients With Major Depressive Disorder (MDD)

Role: lead

NCT03668600Phase 3Terminated

Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD)

Role: lead

NCT03002077Phase 3Completed

Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder

Role: lead

NCT02951988Phase 3Completed

A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder

Role: lead

NCT02943564Phase 3Completed

A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-02)

Role: lead

NCT02192099Phase 2Terminated

Open Label Extension for GLYX13-C-202, NCT01684163

Role: lead

NCT02943577Phase 3Completed

A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-03)

Role: lead

NCT02932943Phase 3Completed

A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01)

Role: lead

NCT02446314Not ApplicableCompleted

An Investigation Into the Effects of a Wild Blueberry Powder and a Wild Blueberry Extract on Cognition in Older Adults

Role: collaborator

NCT03855865Phase 3Withdrawn

Study of Rapastinel as Monotherapy in Major Depressive Disorder (MDD)

Role: lead

NCT03814733Phase 1Completed

Assessment of Effect of Rapastinel on Driving Performance

Role: lead

NCT03799900Phase 1Completed

Assessment of Abuse Potential of Rapastinel in Humans

Role: lead

NCT02067793Phase 2Completed

Study of Intravenous NRX-1074 in Patients With Major Depressive Disorder

Role: lead

NCT01684163Phase 2Completed

Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants

Role: lead

NCT01014650Phase 1Completed

Single Ascending Dose Safety, Tolerability and Pharmacokinetics Study of GLYX-13 in Normal Volunteers

Role: lead

NCT02366364Phase 1Completed

Study of Safety, Tolerability and Pharmacokinetics of NRX-1074 in Normal Healthy Volunteers

Role: lead

NCT02603458Phase 2Withdrawn

NRX-1074 in Early Course Schizophrenia

Role: collaborator